Monday, September 12, 2022 Daily Archives

Enabling Capabilities and Solutions for all mRNA (Nucleic Acid) platforms – Process Development, Manufacturing and Formulation

Conquer the mRNA era. Advancing together from initial idea to final product. Your molecule’s journey to the market is a long and complex one. You need an experienced and trustworthy partner who understands the varying challenges you face and helps you solve them efficiently, safely and speedily. No matter whether you’re still in the idea stage, ready to scale up your production or need specific regulatory know-how for a successful launch of your mRNA drug. From mRNA development and manufacturing…

The Unique Properties of Gelatin in 3D Bioprinting

How to select the right bioink to secure proper cellular characteristics and functionalities in engineered tissues: exploring the benefits of low endotoxin gelatins. Gelatin has long been a trusted excipient in the pharmaceutical industry. For advanced biomedical applications like in-body use, there are strict regulations for endotoxins levels of the final product (medical device) to avoid unwanted side-effects. 3D bioprinting is a very popular tissue engineering technology used in the field of regenerative medicine. In this whitepaper, we explore the…

Overcoming Challenges in Ophthalmic Formulations through Polymer Selection – A Closer Look at Polyvinyl Alcohol

Ophthalmic drug formulations are growing in importance due to the increased prevalence of eye-related disorders such as diabetic retinopathy and macular degeneration. However, ocular drug delivery is challenging due to unique anatomical and physiological barriers such as pre-corneal loss factors including tear turnover, nasolacrimal drainage with potential systemic absorption via the conjunctiva or nasal mucosa, transient residence time, and the relative impermeability of the corneal epithelial membrane. The low ocular bioavailability (<10%) of conventional ophthalmic formulations is driving the need…

NexImmune to use Selexis tech to develop immunotherapies

The partnership will see Selexis and NexImmune collaborate to develop cell lines targeting autoimmune diseases and rare cancers. Under the terms of the deal, of which financial details have not been disclosed, NexImmune will use Selexis’ SUREtechnology to develop cell lines to treat rare cancers, autoimmune diseases, and advance two human leukocyte antigens (HLAs), which can be used to increase treatments to more individuals. “There is a growing global demand for biologics and therapeutics. Specifically, a growing industry is developing…

Takeda and Cryoport team to standardize cell therapy supply chain

A standardized approach to collecting, processing, and storing cell therapy starting materials can reduce variations in manufacturing outcomes and simplify supply chain management, says Cryoport’s CEO. Temperature-controlled supply chain services firm Cryoport has partnered with Takeda’s plasma donation and collection business BioLife Plasma Services to offer standardized cell therapy collection, processing, and storage services for cell therapy products across the US and Europe. The collaboration, of which no financial details have been divulged, aims to establish an integrated GMP-compliant supply…

Podcast: Selecting a CDMO? Know your molecule, know your timeline

With expertise in development and CMC in short supply globally, CDMO choice is absolutely critical for sponsors relying on them to accelerate development pathway, says Pharmatech Associates. Ahead of November’s CPhI Worldwide event in Frankfurt, Germany, BioProcess Insider hosted a LinkedIn Live discussion with Bikash Chatterjee and Stephanie Gaulding, the respective CEO and MD at drug development consultancy firm Pharmatech Associates about current outsourcing strategies and how to go about selecting a CDMO partner. Listen to the full discussion, as…

Investing in small molecule derisks our portfolio, says Bone Therapeutics

Through the reverse merger of Medsenic, Bone Therapeutics will broaden and derisk its portfolio while increasing funding opportunities, the firm says. France-based firm Medsenic specializes in the advancement of optimized formulations of arsenic salts targeting inflammatory conditions and other indications. Under the terms of the deal, Bone Therapeutics will acquire 51 percent of Medsenic shares, valued at $40 million. Together, Bone Therapeutics and Medsenic will create a new biopharma company under the name BioSenic. According to both parties, the integration…